FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804675995> ?p ?o ?g. }

• W2804675995 endingPage "1445" @default.
• W2804675995 startingPage "1436" @default.
• W2804675995 abstract "Abstract Background Folate level was proposed to be a predictor for fluoropyrimidine-related toxicity. We conducted a prospective study to determine the association between serum and red-cell folate and capecitabine-related toxicity in patients with colorectal cancers. Materials and Methods Eligibility criteria included diagnosis of colorectal cancers; eligible patients who were scheduled to undergo capecitabine monotherapy or capecitabine-oxaliplatin (CAPOX) for adjuvant or palliative purposes. Exclusion criteria included concomitant radiotherapy or chemotherapy other than capecitabine or CAPOX and creatinine clearance &lt;30 mL/min. Fasting serum and red-cell folate were measured prior to chemotherapy. Capecitabine was administered at 2,500 mg/m2 per day (monotherapy) or 2,000 mg/m2 per day (CAPOX) for 14 days every 3 weeks. The toxicity of the first four cycles was documented by clinical investigators who were blinded to folate levels. Results A total of 144 patients were recruited, of whom 126 were eligible; 40 patients had capecitabine alone, and 86 patients received CAPOX. The rates of grade 2 and grade 3 toxicity were 63.5% and 14.3%, respectively. Nausea and vomiting were the most common grade ≥2 adverse event (47.7%), followed by hand-foot syndrome (25.4%), diarrhea (23.1%), and neutropenia (22.3%). Combination with oxaliplatin (odds ratio [OR], 2.77; p = .043) and serum folate (OR, 10.33; p = .002) were independent predictors of grade ≥2 toxicity. Red-cell folate was not predictive of toxicity. For every 10 nmol/L increment in serum folate, the risk of grade ≥2 toxicity increased by 9%. Conclusion Serum folate level, but not red-cell folate, was associated with higher rate of grade ≥2 toxicity during capecitabine-based treatment. Excessive folate intake may be avoided before and during capecitabine-based chemotherapy. Implications for Practice This is the first prospective study to evaluate the association between serum folate level and capecitabine-related toxicity in patients with colon cancers. It shows that higher serum folate level is associated with increased risks of moderate to severe toxicity during capecitabine-based treatment. Excessive folate intake should be avoided before and during capecitabine-based chemotherapy." @default.
• W2804675995 created "2018-06-01" @default.
• W2804675995 creator A5022958923 @default.
• W2804675995 creator A5025112401 @default.
• W2804675995 creator A5030823573 @default.
• W2804675995 creator A5031774987 @default.
• W2804675995 creator A5037162882 @default.
• W2804675995 creator A5046498356 @default.
• W2804675995 creator A5074687638 @default.
• W2804675995 creator A5079759838 @default.
• W2804675995 creator A5089150005 @default.
• W2804675995 creator A5090863040 @default.
• W2804675995 date "2018-05-25" @default.
• W2804675995 modified "2023-10-18" @default.
• W2804675995 title "Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer" @default.
• W2804675995 cites W111536681 @default.
• W2804675995 cites W12995195 @default.
• W2804675995 cites W1853577420 @default.
• W2804675995 cites W1910716144 @default.
• W2804675995 cites W1931181957 @default.
• W2804675995 cites W1964748084 @default.
• W2804675995 cites W1971627268 @default.
• W2804675995 cites W1976135397 @default.
• W2804675995 cites W1977168996 @default.
• W2804675995 cites W1978608893 @default.
• W2804675995 cites W2003910285 @default.
• W2804675995 cites W2005356987 @default.
• W2804675995 cites W2034200903 @default.
• W2804675995 cites W2036046459 @default.
• W2804675995 cites W2044970916 @default.
• W2804675995 cites W2046192788 @default.
• W2804675995 cites W2052859309 @default.
• W2804675995 cites W2068045945 @default.
• W2804675995 cites W2100021150 @default.
• W2804675995 cites W2121313610 @default.
• W2804675995 cites W2126200526 @default.
• W2804675995 cites W2138926750 @default.
• W2804675995 cites W2146161922 @default.
• W2804675995 cites W2152511454 @default.
• W2804675995 cites W2158523167 @default.
• W2804675995 cites W2261602114 @default.
• W2804675995 cites W2801096239 @default.
• W2804675995 doi "https://doi.org/10.1634/theoncologist.2017-0637" @default.
• W2804675995 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6292543" @default.
• W2804675995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29802221" @default.
• W2804675995 hasPublicationYear "2018" @default.
• W2804675995 type Work @default.
• W2804675995 sameAs 2804675995 @default.
• W2804675995 citedByCount "7" @default.
• W2804675995 countsByYear W28046759952021 @default.
• W2804675995 countsByYear W28046759952022 @default.
• W2804675995 countsByYear W28046759952023 @default.
• W2804675995 crossrefType "journal-article" @default.
• W2804675995 hasAuthorship W2804675995A5022958923 @default.
• W2804675995 hasAuthorship W2804675995A5025112401 @default.
• W2804675995 hasAuthorship W2804675995A5030823573 @default.
• W2804675995 hasAuthorship W2804675995A5031774987 @default.
• W2804675995 hasAuthorship W2804675995A5037162882 @default.
• W2804675995 hasAuthorship W2804675995A5046498356 @default.
• W2804675995 hasAuthorship W2804675995A5074687638 @default.
• W2804675995 hasAuthorship W2804675995A5079759838 @default.
• W2804675995 hasAuthorship W2804675995A5089150005 @default.
• W2804675995 hasAuthorship W2804675995A5090863040 @default.
• W2804675995 hasBestOaLocation W28046759951 @default.
• W2804675995 hasConcept C121608353 @default.
• W2804675995 hasConcept C126322002 @default.
• W2804675995 hasConcept C143998085 @default.
• W2804675995 hasConcept C197934379 @default.
• W2804675995 hasConcept C2777063308 @default.
• W2804675995 hasConcept C2777909004 @default.
• W2804675995 hasConcept C2780580376 @default.
• W2804675995 hasConcept C2780962732 @default.
• W2804675995 hasConcept C29730261 @default.
• W2804675995 hasConcept C526805850 @default.
• W2804675995 hasConcept C71924100 @default.
• W2804675995 hasConcept C90924648 @default.
• W2804675995 hasConceptScore W2804675995C121608353 @default.
• W2804675995 hasConceptScore W2804675995C126322002 @default.
• W2804675995 hasConceptScore W2804675995C143998085 @default.
• W2804675995 hasConceptScore W2804675995C197934379 @default.
• W2804675995 hasConceptScore W2804675995C2777063308 @default.
• W2804675995 hasConceptScore W2804675995C2777909004 @default.
• W2804675995 hasConceptScore W2804675995C2780580376 @default.
• W2804675995 hasConceptScore W2804675995C2780962732 @default.
• W2804675995 hasConceptScore W2804675995C29730261 @default.
• W2804675995 hasConceptScore W2804675995C526805850 @default.
• W2804675995 hasConceptScore W2804675995C71924100 @default.
• W2804675995 hasConceptScore W2804675995C90924648 @default.
• W2804675995 hasIssue "12" @default.
• W2804675995 hasLocation W28046759951 @default.
• W2804675995 hasLocation W28046759952 @default.
• W2804675995 hasLocation W28046759953 @default.
• W2804675995 hasLocation W28046759954 @default.
• W2804675995 hasOpenAccess W2804675995 @default.
• W2804675995 hasPrimaryLocation W28046759951 @default.
• W2804675995 hasRelatedWork W2011752462 @default.
• W2804675995 hasRelatedWork W2356910782 @default.
• W2804675995 hasRelatedWork W2361275302 @default.

• next